Skip to search formSkip to main contentSkip to account menu

sipuleucel-T Injection [Provenge]

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Currently, there is only one FDA approved cancer vaccine, PROVENGE® (sipuleucel-T). PROVENGE® is a personalized therapy for… 
2016
2016
Although cancer vaccines could not show the evidence of their therapeutic effects in phase III clinical trials, two dendritic… 
Review
2014
Review
2014
Extensive research in the area of active-specific immunotherapy has led to the approval of the first therapeutic cancer vaccine… 
2014
2014
Dendritic cells (DCs) are essential for the initiation of T cell responses and are therefore an attractive target for cancer… 
2013
2013
Prostate cancer (PC) is a malignancy which develops within the male prostate resulting from dietary habits, environmental aspects… 
2013
2013
Immune-based therapies have demonstrated benefit in multiple clinical trials, and as we gain better knowledge of the mechanisms… 
Review
2012
Review
2012
INTRODUCTION Of the cancer gene therapy approaches, gene silencing, suicide/apoptosis inducing gene therapy, immunogene therapy… 
Review
2011
Review
2011
Therapeutic vaccination against cancer is an important approach which, when combined with other therapies, can improve long-term… 
2010
2010
The FDA has approved 2 new treatments for castration-resistant (formerly called hormone-refractory) prostate cancer. Sipuleucel-T…